William Blair analyst Max Smock has maintained their bullish stance on LFCR stock, giving a Buy rating on August 8.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Max Smock has given his Buy rating due to a combination of factors that suggest a promising future for Lifecore Biomedical. The company recently held an analyst day where they reaffirmed their midterm targets and laid out a growth strategy expected to culminate in 2027. This event, which included presentations and discussions with company leaders, left a positive impression on attendees and contributed to a notable increase in the stock price.
Smock’s analysis anticipates that Lifecore will achieve an adjusted EBITDA of $40 million by fiscal 2028. Based on this projection and a forward EBITDA multiple of 16 times, the stock is estimated to reach a value of $10 per share by May 2027. This potential 30% upside from current levels is seen as a compelling opportunity that outweighs the associated execution risks, justifying the Buy rating.
In another report released on August 8, Craig-Hallum also reiterated a Buy rating on the stock with a $10.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFCR in relation to earlier this year.